Optimistic Buy Rating for Gain Therapeutics’ GT-02287 Based on ...
WEB10 hours ago · Gain Therapeutics (GANX) Company Description: Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with ...
Gain Therapeutics to Present Preclinical GT-02287 Data in …
WEB1 day ago · BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and ...
Gain Therapeutics - Unfolding the next generation of allosteric …
WEBGain Therapeutics is a biotech company that develops novel small molecules for neurodegenerative diseases using AI and physics-based methods. Learn about its pipeline, platform, and latest news on its Phase I study of GT-02287 for GBA-Parkinson's disease.
Gain Therapeutics, Inc. (GANX) Stock Price, News, Quote
WEBJul 1, 2024 · Find the latest Gain Therapeutics, Inc. (GANX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Gain Therapeutics to Present Preclinical GT-02287 Data in
WEB1 day ago · About Gain Therapeutics, Inc. Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug ...
Gain Therapeutics Announces the Initiation of the Multiple …
WEBFeb 27, 2024 · Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including ...
Gain Therapeutics Announces Positive Topline Results from the …
WEBAug 29, 2024 · Gain Therapeutics (Nasdaq: GANX) is a biotech company developing GT-02287, a small molecule therapy for Parkinson's disease with or without a GBA1 mutation. The stock price and news include...
Gain Therapeutics Announces Dosing of First Two Subjects in
WEBOct 4, 2023 · Gain Therapeutics’ lead drug candidate, GT-02287, is in development for the treatment of GBA1 Parkinson’s disease (GBA1-PD).
Gain Therapeutics Presents New Preclinical Data - GlobeNewswire
WEBSep 19, 2022 · Gain Therapeutics presents new data on GT-02287, a novel small molecule candidate that may halt disease progression in Parkinson's disease by restoring lysosomal health and enzyme...
Optimistic Outlook for Gain Therapeutics Amid ... - Markets Insider
WEBJul 11, 2024 · Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
Skip to content